Title A Randomized, Phase 2, Open-Label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects with High Risk HER2+Urothelial Carcinoma
Contact EH
Principal Investigator Thomas Schwaab, MD
Study Number 217712
Phase2
Summary To evaluate overall survivor following administration of DN24-02. Also to evaluate disease-free survival following administration of DN24-02. It is anticipated that SOC for the control group will comprise observation only until documentation of disease recurrence.
Eligibility See ClinicalTrials.gov link for current Eligibility criteria.